Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck, Tony S.K. Mok, Makoto Nishio et al. · The Lancet Respiratory Medicine · 2019

Cited by 946 works. doi:10.1016/s2213-2600(19)30084-0

Authors

References